{"schema_version":"1.0","type":"article","title":"FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測","url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.md","lang":"zh-Hant","date":"2026-05-16","publish_at":"2026-05-16T10:30:00+08:00","updated_at":"2026-05-16","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","BD","FDA","生技投資"],"summary":"2026 年 5 月 12 日，美國 FDA 局長 Marty Makary 正式辭職，結束他僅約 13 個月的任期。","key_points":[],"facts":[],"sections":["01｜Marty Makary 為什麼會走到下台？","02｜電子煙只是導火線，真正問題是政治壓力進入 FDA","03｜真正危險的不是換人，而是 FDA 的制度記憶正在流失","04｜幾個案例，正在讓產業重新理解 FDA 風險","05｜為什麼這會影響全球生技估值？","06｜Kyle Diamantas 接手，也不代表問題會自動解決"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/fda-commissioner-makary-is-resigning-politico-reports-2026-05-12/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/fda-commissioner-makary-is-resigning-politico-reports-2026-05-12/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Commissioner's National Priority Voucher (CNPV) Pilot Program","source":"FDA","date":"","url":""},{"title":"FDA Commissioner's National Priority Voucher Program. The Commissioner's National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"FDA Expands Market Access, Authorizes New ENDS Products","source":"FDA","date":"","url":""},{"title":"FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Department of Health and Human Services will lay off 10,000 workers","source":"AP News","date":"","url":""},{"title":"In a major overhaul, the U.S. Department of Health and Human Services will lay off 10,000 workers and shut down entire agencies.","source":"","date":"","url":""},{"title":"apnews.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Top drug regulator Richard Pazdur set to leave the FDA","source":"STAT","date":"","url":""},{"title":"Top drug regulator Richard Pazdur filed papers to retire from the Food and Drug Administration at the end of this month.","source":"","date":"","url":""},{"title":"www.statnews.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"www.accessdata.fda.gov","source":"","date":"","url":""},{"title":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf"},{"title":"www.accessdata.fda.gov","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測","url":"https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-01.webp"},{"alt":"Dcard 原圖：FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測","url":"https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-02.png"},{"alt":"Dcard 原圖：FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測","url":"https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-16）。FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測。https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}